A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity of 8MW2311 administered by intravenous (IV) infusion.
Solid Tumors
DRUG: 8MW2311
AEs, All the adverse events, Up to 28 days post last dose|ORR, Objective Response Rate, Up to 24 months
BOR, Best of Response, Up to 24 months|DCR, Disease Control Rate, Up to 24 months|CBR, Clinical Benefit Rate, Up to 24 months|PFS, Progression-Free Survival, Up to 24 months|DoR, Duration of Remission, Up to 24 months|TTR, Time to Response, Up to 24 months|TTP, Time to Progression, Up to 24 months|OS, Overall Survival, Up to 24 months|PK Parameter AUC, The area under the curve (AUC), Up to 24 months|PK Parameter Cmax, Maximum concentration (Cmax), Up to 24 months|PK Parameter Tmax, Time at which maximum concentration(Tmax), Up to 24 months|PK Parameter T1/2, The half life(T1/2), Up to 24 months|Incidence of ADA, Incidence of Anti-Drug Antibody (ADA), Up to 24 months
This study is a Phase 1/2, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity of 8MW2311 administered by intravenous (IV) infusion.